The incidence of intra-abdominal infection increases annually. The current management of intra-abdominal infection includes immediate resuscitation, prompt source control and appropriate usage of antibiotics. For patients with septic shock, fluid resuscitation should begin immediately when hypotension is present. Fluid resuscitation should be combined with vasoactive drugs. Damage control surgery promotes the development of ultrasound or CT guided percutaneous abscess drainage and open abdomen therapy. Rational use of anti-infective drugs could prevent prevalence of multiple antibiotics resistant bacteria and pan-resistant bacteria. The gut rehabilitation measures can improve the recovery of gut function and restore of enteral nutrition, and thus prevents bacterial translocation in intra-abdominal infection patients. Monitoring and modulations of immune function may further improve the successful rate of treatment of intra-abdominal infections. Non-thyroidal illness syndrome may develop in the severe intra-abdominal infection patients and should be promptly corrected.
Humans ; Intraabdominal Infections ; diagnosis ; therapy

Intra-abdominal infection complicated with hypothyroidism is very common. It mostly featured decreased T3, with or without decreased T4, and without elevated thyroid stimulating hormone(TSH). This particular type of hypothyroidism was called "low T3 syndrome" or "thyroid illness syndrome", and is called "non-thyroid illness syndrome" increasingly in recent years. Its pathogenesis has not been fully understood, and probably is associated with abnormality of hypothalamic-pituitary-thyroid axis, disorder of peripheral thyroid hormone metabolism, change in thyroid hormone binding protein, regulation of triiodothyronine receptors, effect of cytokines, and lack of trace element selenium. Intra-abdominal infection complicated with hypothyroidism should be differentiated from primary hypothyroidism, which may be one cause of mental depression, insufficient anabolism, and poor tissue healing. Therefore, the changes of T3 and T4 levels should be actively monitored in patients with severe or prolonged intra-abdominal infection. Whether treatment is needed for intra-abdominal infection complicated with hypothyroidism remains controversial. T3 replacement therapy may improve prognosis. When low T3 syndrome presents as a disease-mediated hypothyroidism, we recommend the use of levothyroxine(L-T4) or liothyronine (L-T3) treatment to improve the prognosis of critical patients. Enteral nutrition can improve hypothyroidism and has good efficacy for enterocutaneous fistula patients with intra-abdominal infection.
Humans ; Hypothyroidism ; complications ; drug therapy ; Intraabdominal Infections ; complications ; diagnosis ; therapy ; Thyroxine ; therapeutic use ; Triiodothyronine ; therapeutic use

Intra-abdominal infections(IAIs) are common surgical emergencies and complications, which usually need multidisciplinary management including surgeons, intensivists, infectious disease experts, microbiologists, and clinical pharmacists. Based on international and domestic guidelines and recent advances, a number of experts' statements of consensus, with a problem-oriented approach, were made on the cornerstones of effective treatment of IAIs such as early recognition, etiology identification, adequate source control, and appropriate antimicrobial therapy. Main recommendations include concepts of intra-abdominal infection, pathoqen diagnosis precautions; surgical intervention principles and strategies of specific causes including acute appendicitis, upper gastrointestinal perforation, lower gastrointestinal perforation, acute biliary infection, liver abscess, severe acute pancreatitis, pancreatic fistula, biliary fistula, anastomotic leakage, gastrointestinal perforation, as well as perforation due to endoscopic procedure etc.; principles of antimicrobial therapy, dosage of antibiotics in specific population and pathophysiological state; and systematic support of severe infection such as early resuscitation and nutrition support.
Combined Modality Therapy ; Consensus ; Humans ; Intraabdominal Infections/therapy* ; Patient Care Team

BACKGROUND: Clinical significance of viridans streptococcal bacteremia may be variable from insignificant colonization to serious invasive diseases such as endocarditis. However, there have been no data on the clinical implications of viridans streptococcal bacteremia in Korea to date. MATERIALS AND METHODS: We have analyzed 95 cases of viridans streptococcal bacteremia diagnosed at the Samsung Medical Center from 1997 to 2003. All available clinical and microbiological data were analyzed. RESULTS: Of the total 95 cases, 76 (80%) had clinically significant infections, while 20% of cases were not associated with clinical diseases. Primary bacteremia was the most common disease (48%) followed by intra-abdominal infections (15%), and infective endocarditis (8%). Primary bacteremia was mostly observed in patients with neutropenia after anti-cancer chemotherapy. Infective endocarditis was unlikely if patients did not have underlying heart diseases. S. mitis, S. oralis, and S. intermedius were the most common etiologic agent in infective endocarditis, primary bacteremia, and intra-abdominal infection, respectively. Thirty-eight percent of isolates were not susceptible to penicillin. CONCLUSION: Viridans streptococcal bacteremia is likely to be associated with invasive clinical diseases, especially in patients with neutropenia, intra-abdominal diseases or underlying heart diseases. However, the presence of viridans streptococci in the blood cultures does not necessarily mean the possibility of infective endocarditis.
Bacteremia* ; Colon ; Drug Therapy ; Endocarditis ; Heart Diseases ; Humans ; Intraabdominal Infections ; Korea ; Neutropenia ; Penicillins ; Viridans Streptococci*

BACKGROUND: Clinical significance of viridans streptococcal bacteremia may be variable from insignificant colonization to serious invasive diseases such as endocarditis. However, there have been no data on the clinical implications of viridans streptococcal bacteremia in Korea to date. MATERIALS AND METHODS: We have analyzed 95 cases of viridans streptococcal bacteremia diagnosed at the Samsung Medical Center from 1997 to 2003. All available clinical and microbiological data were analyzed. RESULTS: Of the total 95 cases, 76 (80%) had clinically significant infections, while 20% of cases were not associated with clinical diseases. Primary bacteremia was the most common disease (48%) followed by intra-abdominal infections (15%), and infective endocarditis (8%). Primary bacteremia was mostly observed in patients with neutropenia after anti-cancer chemotherapy. Infective endocarditis was unlikely if patients did not have underlying heart diseases. S. mitis, S. oralis, and S. intermedius were the most common etiologic agent in infective endocarditis, primary bacteremia, and intra-abdominal infection, respectively. Thirty-eight percent of isolates were not susceptible to penicillin. CONCLUSION: Viridans streptococcal bacteremia is likely to be associated with invasive clinical diseases, especially in patients with neutropenia, intra-abdominal diseases or underlying heart diseases. However, the presence of viridans streptococci in the blood cultures does not necessarily mean the possibility of infective endocarditis.
Bacteremia* ; Colon ; Drug Therapy ; Endocarditis ; Heart Diseases ; Humans ; Intraabdominal Infections ; Korea ; Neutropenia ; Penicillins ; Viridans Streptococci*

Intra-abdominal infection (IAI) is a deadly condition in which the outcome is associated with urgent diagnosis, assessment and management, including fluid resuscitation, antibiotic administration while obtaining further laboratory results, attaining precise measurements of hemodynamic status, and pursuing source control. This last item makes abdominal sepsis a unique treatment challenge. Delayed or inadequate source control is an independent predictor of poor outcomes and recognizing source control failure is often difficult or impossible. Further complicating issue in the debate is surrounding the timing, adequacy, and procedures of source control. This review evaluated and summarized the current approach and challenges in IAI management, which are the future research directions.
Anti-Bacterial Agents/administration & dosage* ; Drainage ; Fluid Therapy ; Hemodynamics ; Humans ; Intraabdominal Infections/therapy* ; Laparoscopy ; Laparotomy ; Prognosis ; Sepsis

Most of the intra-abdominal infections are benign and critical diseases caused by trauma, surgery and gastrointestinal diseases, which require the attention of surgeons. The increase of drug resistance of pathogens is a common clinical problem. The intra-abdominal infection caused by multidrug-resistant bacteria is a huge challenge faced by clinicians, and is mainly found in hospital-acquired abdominal infections, of which gram-negative bacteria are the most common. This paper firstly summarizes the common types, early diagnosis and risk factors of multidrug-resistant bacteria according to the literature, and then describes the treatment strategy of intra-abdominal infection caused by multidrug-resistant bacteria from four aspects: anti-infective medication, infection source control, resuscitation and organ support, and nutritional support treatment. In addition, we should promote gastrointestinal function recovery through nutritional support treatment and prevent intestinal source infection, on the basis of understanding the risk factors of multidrug-resistant infection, rational use of anti-infective medication and infection source control measures. At the same time, proper organ function support can help to improve the success rate in the treatment of multidrug-resistant intra-abdominal infection.
Abdominal Cavity ; Anti-Bacterial Agents ; Bacteria ; drug effects ; Bacterial Infections ; microbiology ; prevention & control ; therapy ; Cross Infection ; Drug Resistance, Bacterial ; Drug Resistance, Multiple ; Humans ; Intraabdominal Infections

PURPOSETo investigate and analyze the clinical and etiological characteristics of community-acquired intraabdominal infections (CIAIs) and hospital-acquired or nosocomial intraabdominal infections (NIAIs) in a comprehensive hospital, to understand the characteristics, pathogen composition, and drug resistance of CIAIs as well as NIAIs, and to provide a reference for clinical treatment.

METHODSWe collected the clinical data of patients with intraabdominal infections admitted to our hospital from June 2013 to June 2014. In vitro drug sensitivity tests were conducted to separate pathogens, and the data were analyzed using the WHONET 5.4 software and SPSS 13.0 software.

RESULTSA total of 221 patients were enrolled in the study, including 144 with CIAIs (55 mild-moderate and 89 severe) and 77 with NIAIs. We isolated 322 pathogenic strains, including 234 strains of gram-negative bacteria, 82 strains of gram-positive bacteria, and 6 strains of fungi. Based on clinical features, NIAIs and severe CIAIs presented significantly higher values in age, length of hospital stay, mortality, and the incidence of severe intra-abdominal infection than mild-moderate CIAIs (p < 0.05). There was no significant difference in the prognosis between NIAIs and severe CIAIs. Primary diseases leading to CIAIs and NIAIs mostly were hepatobiliary diseases and gastrointestinal diseases respectively. Bacteria isolated from various types of IAIs mainly were Enterobacteriaceae; mild-moderate CIAIs mostly were mono-infection of gram-negative bacteria; NIAIs mostly were mixed infections of gram-negative and gram-positive bacteria; and severe CIAIs were from either type of infection. The rate of Extended Spectrum b-Lactamase-producing Escherichia coli and Klebsiella pneumoniae was much higher in NIAIs than in CIAIs (p < 0.05). The antimicrobial drug sensitivity of gram-negative bacteria isolated from NIAIs was significantly lower than that of CIAIs.

CONCLUSIONCIAIs and NIAIs have their own unique clinical features and epidemiological features of pathogens which should be considered during the initial empiric therapy for the rational use of antimicrobial drugs. Regional IAIs pathogenic bacteria have their own features in drug resistance, slightly different from some recommendations of 2010 Infectious Diseases Society of America guidelines.

Adult ; Aged ; Bacterial Infections ; drug therapy ; epidemiology ; Community-Acquired Infections ; drug therapy ; epidemiology ; microbiology ; Cross Infection ; drug therapy ; epidemiology ; microbiology ; Female ; Humans ; Intraabdominal Infections ; drug therapy ; epidemiology ; microbiology ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Prospective Studies

Psoas abscess is caused by primary or secondary and most commonly results from direct extension of intraabdominal infections. Staphylococcus aureus is the most common organism for psoas abscess secondary to vertebral osteomyelitis. Tuberculosis, malnutrition, alcoholism, diabetes mellitus, bone marrow failure, and steroid use are responsible for compromise in host defense and consequent increase in the relative risk of psoas abscess. We report here a case of bilateral poas abscess developed in a 58 year old patient with relapsed plasmacytoma in pelvic cavity during chemotherapy.
Abscess ; Alcoholism ; Bone Marrow ; Diabetes Mellitus ; Drug Therapy ; Humans ; Intraabdominal Infections ; Malnutrition ; Middle Aged ; Multiple Myeloma* ; Osteomyelitis ; Plasmacytoma ; Poa ; Psoas Abscess* ; Staphylococcus aureus ; Tuberculosis

BACKGROUNDErtapenem has been demonstrated to be highly effective for the treatment of complicated infections. The aim of this study was to compare the efficacy and safety of ertapenem with ceftriaxone.

METHODSWe searched the PubMed, EMBASE, and the Cochrane Library for published randomized controlled trials (RCTs) that compared the efficacy and safety of ertapenem with ceftriaxone for the treatment of complicated infections including community-acquired pneumonia (CAP), complicated urinary tract infections (cUTIs), and complicated intra-abdominal infections (cIAIs). Meta-analysis was performed by RevMan 5.0.

RESULTSEight RCTs, involving 2 883 patients, were included in our meta-analysis. Ertapenem was associated with similar clinical treatment success with ceftriaxone for complicated infections (1 326 patients, fixed-effect model, OR: 1.13, 95% CI: 0.75-1.71). There was no difference between the compared treatment groups with regard to the microbiological treatment success, and no difference was found with regard to the incidence of clinical and laboratory drug-related adverse events between ertapenem and ceftriaxone groups. As to local tolerability, overall, there was no difference between the compared groups; however, in the subgroup analysis, local reaction was significantly less in the ertapenem subgroup than the ceftriaxone plus ceftriaxone subgroup.

CONCLUSIONSErtapenem can be used as effectively and safely as ceftriaxone for the treatment of complicated infections. It is an appealing option for the treatment of these complicated infections.

Anti-Bacterial Agents ; therapeutic use ; Ceftriaxone ; therapeutic use ; Humans ; Intraabdominal Infections ; drug therapy ; Pneumonia ; drug therapy ; Randomized Controlled Trials as Topic ; Urinary Tract Infections ; drug therapy ; beta-Lactams ; therapeutic use